(Q34136565)

31 July 2017

title

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study (English)

1 reference

magnetic resonance imaging

31 July 2017

main subject

0 references

3

Ludwig Kappos

1 reference

31 July 2017

5

Gavin Giovannoni

1 reference

31 July 2017

6

Krzysztof Selmaj

1 reference

31 July 2017

2

Ralf Gold

1 reference

31 July 2017

4

Amit Bar-Or

1 reference

31 July 2017

1

Douglas L Arnold

1 reference

31 July 2017

7

Minhua Yang

1 reference

31 July 2017

11

Katherine T Dawson

1 reference

31 July 2017

Ray Zhang

8

1 reference

31 July 2017

Monica Stephan

series ordinal

9

1 reference

31 July 2017

Sarah I Sheikh

series ordinal

10

1 reference

31 July 2017

publication date

3 July 2014

1 reference

31 July 2017

1 reference

31 July 2017

volume

261

1 reference

31 July 2017

issue

9

1 reference

31 July 2017

page(s)

1794-1802

1 reference

Creative Commons Attribution 4.0 International

31 July 2017

copyright license

start time

3 July 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s00415-014-7412-x

0 references

cites work

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4155185

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4155185

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4155185

Placebo-controlled trial of oral laquinimod for multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4155185

Advances in imaging to support the development of novel therapies for multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4155185

Magnetic Resonance Techniques in Multiple Sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4155185

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4155185

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4155185

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4155185

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4155185

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4155185

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4155185

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4155185

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4155185

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4155185

Defining interferon beta response status in multiple sclerosis patients.

5 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7412-X

The impact of intensity variations in T1-hypointense lesions on clinical correlations in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7412-X

Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7412-X

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7412-X

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7412-X

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7412-X

ICH harmonized tripartite guideline: Guideline for Good Clinical Practice.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4155185

Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24989666

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00415-014-7412-X

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference

31 July 2017

1 reference